Merck's CAPVAXIVE could cover approximately 78% of invasive pneumococcal disease cases in youth with chronic health conditions, vs other approved pneumococcal conjugate vaccines.
A secondary analysis of the DANFLU-2 trial found adults ≥65 receiving a high-dose flu vaccine had a 46% lower risk of myocarditis or pericarditis compared with standard-dose vaccination.